The Effect of Chemotherapy Treatment on Cognitive Impairment and Clinical Symptoms in Hodgkin Lymphoma Patients
Rattachement africain : cz. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND/OBJECTIVES: Cancer- or chemotherapy-related cognitive deficit is a common side effect occurring in patients with Hodgkin lymphoma. No previous study compared the influence of different types of treatment on the onset and development of chemotherapy cognitive impairment in longitudinal design. The aim of this study was to assess whether a more intensive form of chemotherapy causes greater cognitive impairment. METHODS: Forty-four patients at three different stages of the disease and with three different treatments (ABVD + 30 Gy, BEACOPPesc, or ABVD + 30 Gy plus BEACOPPesc) completed the neuropsychological battery and psychological measures of affective distress and quality of life. We compared their cognitive performance before, immediately after, and 6 months after the treatment. RESULTS: Whether or not we divided the total number of people with Hodgkin lymphoma into two groups (mild and moderate disease versus severe disease) or three groups (mild, moderate, and advanced disease), we found no statistically significant difference between the groups in cognitive performance or other psychological factors or experienced quality of life. CONCLUSIONS: Our results did not show that disease stage or treatment protocol had an effect on the depth of cognitive impairment in cancer or chemotherapy. We hypothesize that, in terms of brain health, intensive forms of chemotherapy (6 × BEA-COPPesc) do not pose a greater risk than milder forms (4 × ABVD + 30 Gy IF RT and 2 × BEACOPPesc + 4 × ABVD + 30 Gy IF RT) of cancer treatment for Hodgkin lymphoma. However, a limitation of our study is the small number of participants in the study, so it would be advisable to repeat the study on a larger sample of patients. Confirmation of our results could be beneficial in that neither patients nor physicians need to worry that intensive chemotherapy will worsen cognitive deficits.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The Effect of Chemotherapy Treatment on Cognitive Impairment and Clinical Symptoms in Hodgkin Lymphoma Patients
- Date Crossref
- 28/04/2025
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Charles University pays non établi dans la noticeUniversité ou école supérieure
-
National Institute of Mental Health pays non établi dans la noticeStructure de recherche
-
University Hospital Kralovske Vinohrady Department of Clinical Hematology pays non établi dans la noticeÉtablissement de santé
-
Third Faculty of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
First Faculty of Medicine pays non établi dans la noticeUniversité ou école supérieure
Charles University, National Institute of Mental Health et Department of Clinical Hematology — University Hospital Kralovske Vinohrady, avec 2 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.